高脂血症性胰腺炎的研究进展

Recent Developments in the Management of Hyperlipidemic Pancreatitis

高脂血症已成为急性胰腺炎的主要病因之一,且高脂血症性胰腺炎(HLP)发病率逐年升高,但临床上对HLP的相关发病机制及诊治认识不足,加上其发病和治疗有一定的特异性,HLP的诊治易被延误。降脂药物、血液净化、低分子肝素、胰岛素、分子生物学治疗等是治疗HLP的主要措施,改变生活方式和控制诱发因素是预防本病的关键。HLP的确切发病机制目前仍不清楚,但随着研究的深入,已经对其发病机制有了进一步认识;同时因血液净化技术的发展、分子生物学治疗的革新,HLP的诊治已经有了质的飞跃,本文就HLP的诊治进展做一综述。

Hyperlipidemia has become one of the leading causes of acute pancreatitis. Although the incidence of hyperlipidemic pancreatitis（ HLP） increases year by year,its management is likely to be delayed due to clinical insufficient understanding of its pathogenesis and management as well as the specificity in its incidence and treatment. Lipid- lowering drugs,blood purification,1ow molecular heparin,insulin as well as molecular biotherapy,are the main measures which have been widely used for the treatment of HLP. Changing the lifestyle and controlling risk factors are the keys to preventing HLP. The exact pathogenesis of HLP remains unclear,but with the development of the research, further consensus has been achieved in its pathogenesis. Furthermore,with the development of blood purification technique, innovation of molecular biotherapy, the management of HLP has been improved greatly. In view of this,this article reviewed the recent developments in the management of HLP.